Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Z-BEAM + ASCT
- Development stage
- Unknown
- Lead developer
- City of Hope Medical Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Z-BEAM + ASCT is an intensified conditioning regimen used prior to autologous stem cell transplantation (ASCT) for patients with relapsed or poor-risk B-cell non-Hodgkin lymphoma. The regimen incorporates the radioimmunotherapy agent Zevalin (yttrium Y 90 ibritumomab tiuxetan), which targets the CD20 antigen on B-cells to deliver localized beta radiation, alongside the standard BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan). Rituximab is also typically administered as part of the protocol. This combination aims to enhance the cytoreductive effect on malignant B-cells through multiple mechanisms, including targeted radiation, antibody-dependent cellular cytotoxicity, and DNA damage from alkylating agents and antimetabolites, thereby improving outcomes in aggressive or refractory lymphomas.
- Other names
- Z-City of Hope Medical Center-B-cell non-Hodgkin lymphomaZ-BEAMZevalin-BEAMyttrium Y 90 ibritumomab tiuxetan + rituximab + carmustine + etoposide + cytarabine + melphalan + autologous stem cell transplant
02
Targets
Beyond the preview
Go deeper on Z-BEAM + ASCT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Z-BEAM + ASCT.